Technical Analysis for SPHS - Sophiris Bio

Grade Last Price % Change Price Change
grade A 0.27 2.86% 0.0075
SPHS closed up 2.86 percent on Thursday, April 9, 2020, on 47 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
Historical SPHS trend table...

Date Alert Name Type % Chg
Outside Day Range Expansion 0.00%
NR7 Range Contraction 2.86%
NR7-2 Range Contraction 2.86%
Calm After Storm Range Contraction 0.07%
NR7 Range Contraction 0.07%
Inside Day Range Contraction 0.07%
Calm After Storm Range Contraction 12.50%
Outside Day Range Expansion 12.50%
Hot IPO Pullback Bullish Swing Setup 17.39%
Calm After Storm Range Contraction 17.39%
Older signals for SPHS ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.
Medicine Medical Specialties RTT Biopharmaceutical Clinical Medicine Diseases Prostate Cancer Benign Prostatic Hyperplasia Men's Health Urological Diseases Urology Andrology Bph Prostate Prostatitis Johns Hopkins University The Johns Hopkins University Treatment Of Urological Diseases

Is SPHS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 0.36
52 Week Low 0.12
Average Volume 213,922
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.2589
Average True Range 0.0636
ADX 0.0
+DI 16.8145
-DI 8.6878
Chandelier Exit (Long, 3 ATRs ) 0.1692
Chandelier Exit (Short, 3 ATRs ) 0.3108
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0228
MACD Signal Line 0.0144
MACD Histogram 0.0084
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.3375
Resistance 3 (R3) 0.3300 0.3000 0.3263
Resistance 2 (R2) 0.3000 0.2828 0.3038 0.3225
Resistance 1 (R1) 0.2850 0.2722 0.2925 0.2925 0.3187
Pivot Point 0.2550 0.2550 0.2588 0.2588 0.2550
Support 1 (S1) 0.2400 0.2378 0.2475 0.2475 0.2213
Support 2 (S2) 0.2100 0.2272 0.2138 0.2175
Support 3 (S3) 0.1950 0.2100 0.2138
Support 4 (S4) 0.2025